We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 82.50 | 80.00 | 85.00 | 82.50 | 82.50 | 82.50 | 10,130 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Computers | 1.03M | -2.92M | -0.2188 | -3.77 | 11M |
TIDMFDBK
RNS Number : 9462A
Feedback PLC
30 March 2017
30 March 2017
Feedback plc
("Feedback", the "Group" or the "Company")
Letter of Intent signed with leading global medical imaging company and trading update
Feedback plc (AIM: FDBK), the medical imaging software company, is pleased to update shareholders on current developments. The Group's efforts are being concentrated on obtaining the CE mark for TexRAD Lung by the target date of May 2017. The CE mark will allow the sale of TexRAD Lung in the EU and certain other markets as a medical device which provides analysis of PET/CT images for clinical use. As part of the intended distribution arrangements, Feedback's subsidiary company, Cambridge Computed Imaging Ltd ("CCI"), has signed a Letter of Intent with a leading global medical imaging company which would make TexRAD Lung available for purchase on its diagnostic imaging solutions platform. This would, in due course, enable easy access to TexRAD Lung for hundreds of potential users around the world on a subscription basis.
CCI continues to pursue its ongoing discussions with other leading imaging companies to broaden the range of potential routes to market for clinical versions of TexRAD. CCI has also been very active in finalising arrangements for the secure transfer of patient data from Papworth Hospital NHS Foundation Trust to the new Cambridge Biomedical Campus ahead of the move there in April 2018. CCI has provided and maintained the software to store and display medical images at Papworth Hospital since 2001 and is excited at the challenge of transferring the extensive archive of medical images.
New purchase orders for the well-established TexRAD research version are continuing at a good rate ahead of the impending release of the first clinical version with keen interest being shown in India, the US and the UK. There remain significant opportunities for TexRAD in China and South Korea and some additional professional and legal costs have been incurred regarding advice on new distribution and licensing agreements which could substantially increase future revenues. As previously indicated, TexRAD-related revenue in the second half of the Company's financial year is expected to be substantially ahead of that reported for the first half and the Company is on track to report increased revenue for the financial year as a whole.
For further information contact:
Feedback plc Tel: 01954 718072 Alastair Riddell Allenby Capital Limited (Nominated Tel: 020 3328 Adviser and Joint Broker) 5656 David Worlidge / Virginia Bull/ James Thomas Northland Capital Partners Ltd (Joint Tel: 020 3861 Broker) 6625 Patrick Claridge / Margarita Mitropoulou Peterhouse Corporate Finance Ltd Tel: 020 7469 (Joint Broker) 0936 Lucy Williams / Duncan Vasey
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLLFERVEIAFID
(END) Dow Jones Newswires
March 30, 2017 02:00 ET (06:00 GMT)
1 Year Feedback Chart |
1 Month Feedback Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions